Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
BETHESDA, Md., April 04, 2017 -- India Globalization Capital Inc. (NYSE MKT:IGC) announces that on April 3, 2017, it received a NYSE MKT LLC notice indicating that the Company has fallen below certain NYSE MKT continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on March 31, 2016, as set forth in Section 704 of the Company Guide.
To regain compliance, the Company will hold the annual meeting promptly after filing its Form 10-K for fiscal year ended March 31, 2017, which is due by June 30, 2017, following the submission of a plan in form prescribed by the NYSE MKT LLC by April 10, 2017.
About IGC
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life-altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.
For more information visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see forward-looking statements as discussed in detail in IGC's Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports filed with the U.S. Securities and Exchange Commission.
Contact Info: Claudia Grimaldi 301-983-0998
